Tom1 Activators
Tom1 (Target of Myb1) proteins are involved in intracellular trafficking and signaling pathways, playing a role in the regulation of vesicular transport and protein sorting. Activators of Tom1, which could be termed Tom1 Activators, would be a class of chemicals that enhance the functional activity of the Tom1 protein. These activators could operate through direct or indirect mechanisms to increase the protein's activity within cellular processes.
Direct Tom1 Activators would likely interact with the protein at specific sites, inducing a conformational change that results in an increase in Tom1's functional activity. This could involve either binding to the active site of Tom1 and promoting its activity or binding to an allosteric site, which is a separate location on the protein that, when bound by an activator, alters the protein's shape and activity. The change in conformation could increase the affinity of Tom1 for its substrates or partners, enhance its enzymatic activity, or stabilize the protein against degradation. Indirect Tom1 Activators would affect Tom1 activity through modulation of the cellular environment or signaling pathways that affect Tom1. This could include upregulating the transcription of the Tom1 gene, thereby increasing the amount of the protein in the cell. Alternatively, indirect activators might inhibit pathways that lead to the degradation of Tom1, thus prolonging its presence and activity within the cell. They could also initiate post-translational modifications of Tom1, such as phosphorylation or ubiquitination, that alter its activity, localization, or interactions with other proteins.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of JNK. JNK inhibition can lead to reduced phosphorylation of certain proteins which may have inhibitory effects on Tom1, thus potentially enhancing Tom1 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, this compound can suppress Akt signaling. Akt has been shown to inhibit Tom1, so LY294002 can indirectly enhance Tom1 activity by inhibiting Akt activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. p38 MAPK inhibition can lead to decreased phosphorylation of proteins that may negatively regulate Tom1, thus indirectly enhancing Tom1 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family kinases. Src family kinases are known to phosphorylate and inactivate several proteins, potentially including Tom1. By inhibiting Src family kinases, PP2 can potentially enhance Tom1 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor, similar to LY294002. It can suppress Akt signaling and thus potentially enhance Tom1 activity by inhibiting Akt activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK1. It suppresses ERK phosphorylation, which can inhibit Tom1 activity. Therefore, PD98059 can indirectly enhance Tom1 activity by preventing ERK activation. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
ZM336372 is a Raf-1 kinase inhibitor. By inhibiting Raf-1, ZM336372 can suppress downstream ERK activation, which may inhibit Tom1 activity. Therefore, ZM336372 can indirectly enhance Tom1 activity by inhibiting Raf-1 and downstream ERK activation. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
NSC23766 is a Rac1 inhibitor. By inhibiting Rac1, NSC23766 can suppress downstream JNK activation, which may have inhibitory effects on Tom1. Therefore, NSC23766 can indirectly enhance Tom1 activity by inhibiting Rac1 and downstream JNK activation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK proteins. By inhibiting ROCK, Y-27632 can suppress downstream JNK activation, which may inhibit Tom1 activity. Therefore, Y-27632 can potentially enhance Tom1 activity by inhibiting ROCK and downstream JNK activation. | ||||||
Pyrrolidinedithiocarbamic acid ammonium salt | 5108-96-3 | sc-203224 sc-203224A | 5 g 25 g | $32.00 $63.00 | 11 | |
PDTC is an NF-kB inhibitor. NF-kB activation can lead to the expression of proteins that may inhibit Tom1. Therefore, PDTC can potentially enhance Tom1 activity by inhibiting NF-kB activation. | ||||||